Skip to main content

Table 2 Results of reclassification of CECT score after additional review of PET/MRI and CA 19–9

From: Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19–9

 

Reclassification towards > 3

Reclassification towards ≤ 3

CECT score

CECT plus PET/MRI

No. of cases

CECT plus PET/MRI

No. of cases

1 (n = 25)

4

1 (4.0%)

1

18 (72.0%)

5

0

2

2 (8.0%)

  

3

4 (16.0%)

2 (n = 8)

4

2 (25.0%)

1

1 (12.5%)

5

2 (25.0%)

2

3 (37.5%)

  

3

0

3 (n = 23)

4

18 (78.3%)

1

0

5

1 (4.3%)

2

1 (4.3%)

  

3

3 (13.0%)

4 (n = 42)

4

28 (66.7%)

1

0

5

12 (28.6%)

2

1 (2.4%)

  

3

1 (2.4%)

5 (n = 22)

4

0 (%)

1

0

5

22 (100.0%)

2

0

  

3

0

CECT score

CECT plus PET plus CA19-9

No. of cases

CECT plus PET plus CA19-9

No. of cases

1 (n = 25)

4

0

1

19 (76.0%)

5

0

2

5 (20.0%)

  

3

1 (4.0%)

2 (n = 8)

4

1 (12.5%)

1

1 (12.5%)

5

1 (12.5%)

2

4 (50.0%)

  

3

1 (12.5%)

3 (n = 23)

4

17 (73.9%)

1

0

5

1 (4.3%)

2

1 (4.3%)

  

3

4 (17.4%)

4 (n = 42)

4

29 (69.0%)

1

0

5

11 (26.2%)

2

1 (2.4%)

  

3

1 (2.4%)

5 (n = 22)

4

0

1

0

5

22 (100.0%)

2

0

  

3

0

  1. CECT Contrast-enhanced CT, PET Positron emission tomography, CA 19–9 Carbohydrate antigen 19–9